Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312221 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
A Phase 3 study, sponsored by Purdue Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
NCT00312221 is a Phase 3 study that was terminated before completion, run by Purdue Pharma. The registered enrollment target is 418 participants.
The verdict
NCT00312221, a Phase 3 study, was terminated before completion, sponsored by Purdue Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in subjects with moderate to severe osteoarthritis pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in addition to study drug.
Interventions
- DRUG Buprenorphine
- DRUG oxycodone immediate-release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312221
The ClinicalTrials.gov registry entry for NCT00312221 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Buprenorphine is the first listed.
NCT00312221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00312221 about?
NCT00312221 is a clinical study titled "Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain". The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in subjects with moderate to severe osteoarthritis pain currently treated with...
What is the current status of trial NCT00312221?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2004-04. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00312221?
The interventions under investigation include: Buprenorphine (DRUG), oxycodone immediate-release (DRUG).
Who is sponsoring clinical trial NCT00312221?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.